GU Cancers 2026 | 177Lu-PSMA-617 after sipuleucel-T in mCRPC: PRECISION analysis
Neal Shore, MD, FACS, Carolina Urologic Research Center, Myrtle Beach, SC, discusses real-world outcomes of 177Lu-PSMA-617 following sipuleucel-T treatment in metastatic castration-resistant prostate cancer (mCRPC) using the PRECISION data platform. This retrospective observational study evaluated patients who had previously received sipuleucel-T, a population lacking prior effectiveness data. The median progression-free survival observed was comparable to results from the VISION trial (NCT03511664) and PSMAfore trial (NCT04689828), suggesting lutetium-177-PSMA-617 can be effectively sequenced after sipuleucel-T in appropriate patients with metastatic castration-resistant prostate cancer. This interview took place at the 2026 ASCO GU Cancers Symposium in San Francisco, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
